

506
NA
84:11

DISPLAY

JUNE 1987

VOLUME 84

NUMBER 11

UNIVERSITY OF WASHIA

JUN 15 1987

LIBRARIES

BB



NATURAL SCIENCES

Proceedings OF THE National Academy of Sciences

OF THE UNITED STATES OF AMERICA

Proceedings
OF THE
National Academy
of Sciences
OF THE UNITED STATES OF AMERICA

*Officers
of the
Academy*

FRANK PRESS, *President*
JAMES D. EBERT, *Vice President*
BRYCE CRAWFORD, JR., *Home Secretary*
WILLIAM E. GORDON, *Foreign Secretary*
ELKAN R. BLOUT, *Treasurer*

*Editorial Board
of the
Proceedings*

ROBERT H. ABELES	MAXINE F. SINGER, <i>Chairman</i>	HERBERT E. SCARF
GORDON A. BAYM	MARY-DELL CHILTON	SOLOMON H. SNYDER
WILLIAM F. BRACE	EDWARD E. DAVID, JR.	HAROLD VARMUS
RONALD BRESLOW	STUART A. KORNFELD	THOMAS A. WALDMANN
MICHAEL J. CHAMBERLIN	DANIEL E. KOSHLAND, JR.	FRANK H. WESTHEIMER
	PETER D. LAX	
	DANIEL NATHANS	

Managing Editor: FRANCES R. ZWANZIG
Senior Associate Editor: GARY T. COCKS
Associate Editor: CAY BUTLER
Associate Editor: JOHN M. MALLOY
Associate Editor: MARILYN J. MASON
Associate Editor: JANET L. MORGAN
Associate Editor: T. PEARSON
Associate Editor: DOROTHY P. SMITH
Associate Editor: COLENE WALDEN
Assistant Managing Editor: JOANNE D'AMICO

Senior Production Editor: LYNN A. WASSYNG
Production Editors: GAYLE I. ARMSTRONG, BARBARA A. BACON, RUTH E. CROSSGROVE,
SCOTT C. HERMAN, MARGARET M. MADELEINE, JANET L. OVERTON,
KATHLEEN RUBY, DON C. TIPPAN, DEBORAH I. WEINER
Administrative Assistants: DELORES BANKS, CYNDY MATHEWS
Manuscript Coordinators: EVELYN JARMON, JACQUELINE PERRY
Circulation: JULIA LITTLE, VIRGINIA TREADWAY

Editorial correspondence: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 2101 Constitution Avenue, Washington, DC 20418.

Business correspondence: Circulation Office of the PROCEEDINGS, National Academy of Sciences, 2101 Constitution Avenue, Washington, DC 20418.

Information for Contributors: See issue Number 1, January 1987.

Copyright: The National Academy of Sciences has copyrighted this journal as a collective work and does not own copyrights for individual articles. Requests for permission to reproduce parts of individual articles or for reprints of individual articles should be addressed to the authors. Microforms of complete volumes are available to regular subscribers only and may be obtained from University Microfilms, Xerox Corporation, Ann Arbor, MI 48103.

Subscriptions: All correspondence concerning subscriptions should be addressed to the Circulation Office of the PROCEEDINGS. Subscriptions are entered on a calendar year basis only. For 1987, subscription rates are as follows—in the United States: student/postdoctoral, \$65; personal, \$185; institutional, \$215; elsewhere: student/postdoctoral, \$100; personal, \$220; institutional, \$250. Information regarding air mail postage rates is available from the Circulation Office. Subscribers are requested to notify the Circulation Office of the PROCEEDINGS 6 weeks in advance of any change of address; also the local postmaster. The Academy is not responsible for nonreceipt of issues because of an improper address unless a change of address is on file. The notice of address change should list both the old and new addresses. Claims for replacement copies will not be honored more than 60 days after the issue date for domestic subscribers and not more than 90 days after the issue date for foreign subscribers.

Back Issues: Volumes 79–83, January 1982 and thereafter, are available from the Circulation Office of the PROCEEDINGS. The price of a single issue is \$13.00.

Second class postage paid at Washington, DC, and at additional mailing offices.

PRINTED IN THE USA

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (ISSN-0027-8424) is published semimonthly by THE NATIONAL ACADEMY OF SCIENCES, 2101 Constitution Avenue, Washington, DC 20418.

© 1987 by THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

POSTMASTER: Send address changes to: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2101 Constitution Ave., Washington, DC 20418.

Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus

(acquired immunodeficiency syndrome/receptor mimicry/T-lymphocyte surface molecule)

TRAN C. CHANH, GORDON R. DREESMAN, AND RONALD C. KENNEDY*

Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, TX 78284

Communicated by Alfred Nisonoff, February 20, 1987

ABSTRACT A monoclonal anti-idiotypic (anti-Id) antibody, HF1.7, was generated against anti-Leu-3a, a mouse monoclonal antibody (mAb) specific for the CD4 molecule on human helper/inducer T lymphocytes. The anti-Id nature of HF1.7 was demonstrated by the following properties. (i) It reacted in a solid-phase immunoassay with anti-Leu-3a and not with a panel of irrelevant mouse mAbs. (ii) It partially inhibited the binding of anti-Leu-3a to CD4⁺ T cells. (iii) It detected a common idio type present on various anti-CD4 mAbs. Because the CD4 molecule represents the receptor site for human immunodeficiency virus (HIV), the etiologic viral agent of acquired immunodeficiency syndrome, we examined the ability of the anti-Id mAb HF1.7 to mimic CD4 and bind HIV. This anti-Id mAb reacted with HIV antigens in commercial HIV ELISAs and recognized HIV-infected human T cells but not uninfected cells when analyzed by flow cytometry. Attesting further to the HIV specificity, the anti-Id mAb reacted with a recombinant gp160 peptide and a molecule of M_r 110,000-120,000 in immunoblot analysis of HIV-infected cell lysates. The anti-Id mAb also partially neutralized HIV infection of human T cells *in vitro*. These results strongly suggest that this anti-Id mAb mimics the CD4 antigenic determinants involved in binding to HIV.

Acquired immunodeficiency syndrome (AIDS) is a devastating disease resulting from infection of many cellular components vital for the maintenance of immune homeostasis. Human immunodeficiency virus [HIV; also called human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), and AIDS-associated retrovirus (ARV)], the etiologic agent of AIDS, is lymphotropic for cells expressing the CD4 molecule. HIV has been shown to infect not only the helper/inducer subset of T lymphocytes but also cells of the monocyte/macrophage lineage (1-4). *In vitro* infection by HIV can be effectively blocked by monoclonal antibodies (mAbs), such as anti-Leu-3a and OKT4A, directed against the CD4 target molecule (4-6). It has been shown recently (7) that HIV binds to the CD4 molecule via an envelope glycoprotein of M_r 110,000. These results imply that the CD4 antigenic determinants recognized by anti-Leu-3a and OKT4A either represent the site of attachment of HIV or are closely associated with it. Based on Jerne's idio type network hypothesis (8), anti-idio type (anti-Id, or Ab-2) against anti-Leu-3a or OKT4A (Ab-1) bearing the internal image should mimic the antigen (CD4) and bind to HIV envelope glycoprotein. This interaction in turn may inhibit the binding of HIV to CD4 on target cells and therefore could lead to viral inactivation.

A monoclonal anti-Id antibody, termed HF1.7, was generated against mAb anti-Leu-3a. HF1.7 exhibited the following properties. (i) It reacted in solid-phase enzyme-linked

immunosorbent assay (ELISA) with anti-Leu-3a and not with a panel of irrelevant mouse mAbs. (ii) It partially inhibited the binding of anti-Leu-3a to CD4⁺ T cells. (iii) It reacted with HIV antigens in commercial HTLV-III and LAV ELISAs. (iv) It reacted by viable membrane immunofluorescence assay with HIV-infected human T cells but not uninfected cells. (v) It bound to a molecule of M_r 110,000-120,000 in immunoblot analysis of HIV-infected-cell lysate. (vi) It bound a recombinant gp160 peptide by a double-antibody radioimmunoassay (RIA). (vii) The binding of anti-Leu-3a to its anti-Id mAb was inhibited by mAbs against CD4 but not by irrelevant mAbs. (viii) It partially neutralized HIV infection of human T cells *in vitro*. These results strongly suggest that mAb HF1.7 reacts with an idio type (Id) determinant on anti-Leu-3a and mimics part(s) of the CD4 molecule that represents the viral receptor for HIV and binds to HIV envelope glycoprotein. This binding may prevent the virus from attaching to target cells, resulting in viral neutralization. mAb HF1.7 may be an important reagent in the understanding of the molecular mechanism of HIV pathogenicity and in the development of diagnostic and therapeutic strategies.

MATERIALS AND METHODS

mAbs. The CD4-specific mAbs anti-Leu-3a (Becton Dickinson), OKT4A (Ortho Diagnostics), and anti-T4 (Coulter Immunology) were purchased from their manufacturer as purified immunoglobulins or were the gift of G. Thornton (Johnson and Johnson Biotechnology Center, La Jolla, CA). mAbs that recognize other lymphocyte phenotypic markers (Leu-1, Leu-2a, Leu-5b, Leu-8, Leu-M1) were purchased as purified immunoglobulins from Becton Dickinson.

Generation of Monoclonal Anti-Id Antibodies. Three- to five-week-old BALB/c mice were immunized intravenously with purified anti-Leu-3a mAb (30 μ g per mouse) in 0.9% NaCl. Six injections were given at weekly intervals. Three days after the last injection, the mice were killed and their spleen cells were fused with the mouse myeloma cell line NS-1 as described previously (9). Supernatant fluids from wells with hybrid growth were screened for reactivity against HIV or anti-Leu-3a by an ELISA described below.

ELISAs. The HTLV-III ELISA (Electro-Nucleonics, Silver Spring, MD) and the LAV EIA (Genetic Systems, Seattle, WA) were done according to the manufacturers' specifications. Horseradish peroxidase-conjugated goat anti-mouse IgG antibodies (Vector Laboratories, Burlingame, CA) were substituted for goat anti-human IgG enzyme

Abbreviations: AIDS, acquired immunodeficiency syndrome; FITC, fluorescein isothiocyanate; HIV, human immunodeficiency virus; Id, idio type (idio type); mAb, monoclonal antibody; SV40 T antigen, simian virus 40 large tumor antigen; TCID₅₀, 50% tissue culture infective dose.

*To whom reprint requests should be addressed at: Department of Virology and Immunology, Southwest Foundation for Biomedical Research, P.O. Box 28147, San Antonio, TX 78284.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Table 1. Reactivity of mAb HF1.7 with HIV antigens in ELISA

mAb	HTLV-III ELISA	LAV EIA	Psoralen- and UV-inactivated HIV
Negative control anti-Id	0.05 ± 0.01	0.06 ± 0.01	0.04 ± 0.01
Pooled AIDS serum*	1.20 ± 0.11	1.45 ± 0.15	1.01 ± 0.10
HF1.7 anti-Id	0.75 ± 0.08	1.20 ± 0.10	0.45 ± 0.03

Each value represents the mean ± SEM of triplicate determinations. See *Materials and Methods* for descriptions of the assays.

*Diluted 1:300.

conjugate. The ELISA using psoralen- and UV-inactivated HIV was done as described (10).

To determine the binding of HF1.7 to anti-Leu-3a, ascites fluid containing HF1.7 or a control anti-Id mAb (GB-2, which recognizes an idiotype associated with a mAb specific for hepatitis B surface antigen) was fractionated with 50%-saturated ammonium sulfate. The resulting immunoglobulin-containing precipitate was resuspended in borate-buffered saline (0.05 M, pH 8.2), and the concentration of antibody was determined, using an extinction coefficient of 14 for a 1% solution at 280 nm. Various concentrations of the anti-Id mAbs were adsorbed to triplicate wells of microtiter plates. After nonspecific sites were blocked by incubation with 10% normal goat serum in borate-buffered saline, either biotinylated anti-Leu-3a or a biotinylated control mAb specific for simian virus 40 large tumor antigen (SV40 T antigen) (11) was added. (The antibodies had been biotinylated at a concentration of 7 mg/ml, and a 1:1000 dilution in 10% normal goat serum was used in the assay.) After a 1-hr incubation at 37°C, unbound antibodies were removed by washing, and specific binding was detected by using avidin-horseradish peroxidase and followed by 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) with H₂O₂. This assay was performed according to methods previously described (12).

Inhibition of Binding of Anti-Id mAb HF1.7 to mAb Anti-Leu-3a. Microtiter plates were coated with purified HF1.7 (500 ng per well). After blocking of nonspecific sites, 5 µg of various inhibitors were added to the anti-Id-coated wells for 1 hr. After incubation and washing to remove unbound antibodies, biotinylated anti-Leu-3a at a 1:1000 dilution was added and the ELISA was done as described above.

Immunofluorescence Staining. The immunofluorescence staining procedure was performed essentially as described (13). In brief, 10⁶ cells were incubated with anti-Id HF1.7 or a negative antibody control of the same isotype for 30 min at 4°C, followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Cappel Laboratories, Cochranville, PA) for an additional 30 min at 4°C. After incubation,

the cells were washed, fixed in 0.37% formaldehyde, and analyzed by flow cytometry using a Becton Dickinson FACS analyzer interfaced to a BD Consort 30 (Becton Dickinson). To assess the inhibition of binding of anti-Leu-3a to CD4⁺ cells by HF1.7, the human T-cell line CEM A3.01 was used (14). FITC-anti-Leu-3a (Becton Dickinson) was incubated with phosphate-buffered saline (PBS: 0.02 M, pH 7.4) or with PBS containing purified HF1.7 or control anti-Id mAb (10 µg) for 1 hr at 4°C and then was added to 5 × 10⁵ A3.01 cells. The cells were incubated for 30 min at 4°C, washed twice, and analyzed on the FACS.

Immunoblot Analysis. The Bio-Rad Immunoblot System (Bio-Rad Laboratories) was used. In brief, nitrocellulose strips on which electrophoretically fractionated HIV antigens had been blotted were incubated in 20 mM Tris-HCl/150 mM NaCl, pH 7.4/1% bovine serum albumin/0.2% Tween 20 to block nonspecific sites. The strips then were treated with pooled human AIDS sera (1:100) or 3-fold concentrated hybridoma supernatants containing anti-Id antibodies overnight at 4°C. The strips were washed with Tris-HCl buffer to remove unbound antibodies. Human and mouse antibody reactivities were detected with alkaline phosphatase-conjugated goat anti-human immunoglobulin and anti-mouse immunoglobulin (Sigma), respectively. The substrate used was provided by Bio-Rad Laboratories.

Binding to Recombinant HIV Envelope Antigens. A recombinant gp160 peptide produced in the baculovirus expression-vector system and purified by lectin chromatography (Micro Gene Sys, West Haven, CT) was radiolabeled with ¹²⁵I by the chloramine-T reaction (15). Unreacted ¹²⁵I was removed by passage through a PD-10 column (Pharmacia). Approximately 92% of the radiolabel precipitated with protein in 10% trichloroacetic acid. A double-antibody RIA, similar to methods described in ref. 16, was performed using a hyperimmune rabbit anti-mouse IgG to precipitate all the mouse IgG that bound the ¹²⁵I-labeled gp160.

Neutralization of HIV Infection *in Vitro*. The neutralization assay was done as described (17). In brief, 1000 or 100 TCID₅₀




FIG. 1. Binding of biotinylated anti-Leu-3a to anti-Id mAb HF1.7. Microtiter wells were coated with various amounts of HF1.7 mAb (●) or GB-2 control anti-Id mAb of the same isotype (○) and treated with biotinylated anti-Leu-3a (A) or biotinylated antibodies to SV40 T antigen (B).

(see below for definition) of HIV in 100 μ l was incubated with 100 μ l of HF1.7 or GB-2 control anti-Id or culture medium for 1 hr at 37°C. The concentrations of mAbs were adjusted to yield a final concentration of 0.5 mg/ml. After incubation, the treated HIV were added to 10⁶ A3.01 cells and incubated at 37°C for 2 hr in the presence of Polybrene (Calbiochem) at 10 μ g/ml. The cells were then washed and resuspended (10⁶ per ml) in RPMI 1640 medium supplemented with 10% fetal bovine serum. At various times, aliquots of culture fluids were removed and reverse transcriptase (RNA-directed DNA polymerase, EC 2.7.7.49) activity was determined as described (17). Cell-free HIV was harvested from infected A3.01 cell culture and titrated on uninfected A3.01 cells, and the titer was expressed as 50% tissue culture infective dose (TCID₅₀).

RESULTS

Because our primary goal was to obtain mAbs reactive with HIV antigens, we chose to screen the hybrids by ELISA with HIV antigen-coated plates (Table 1). Among 389 hybrids tested, two were found that reacted in all three assays used. Thirty-five hybrids reacted with the immunizing antigen, mAb anti-Leu-3a (data not shown). One of the two hybridomas producing mAbs reactive with HIV antigens, designated HF1.7, was cloned twice by limiting dilution. The isotype of mAb HF1.7 was determined to be IgM.

To assess the specificity of HF1.7 binding, microtiter plates were coated with various concentrations of HF1.7 or a control mAb, GB-2, and allowed to react with biotinylated anti-Leu-3a (Fig. 1A) or biotinylated control mAb of the same isotype as anti-Leu-3a but recognizing SV40 T antigen (Fig. 1B). Anti-Id mAb HF1.7 specifically bound to the biotinylated anti-Leu-3a, whereas no binding was observed between the biotinylated anti-Leu-3a and the control anti-Id mAb. Neither HF1.7 nor the control anti-Id mAb bound to biotinylated control mAb specific for SV40 T antigen. Anti-Id HF1.7 did not react with a panel of irrelevant murine mAbs that included anti-Leu-1, -Leu-2a, -Leu-5b, -Leu-8, and -Leu-M1 or with normal mouse IgG.

At a concentration of 5 μ g, the irrelevant mAbs failed to significantly inhibit the binding of anti-Leu-3a to its anti-Id mAb (range of inhibition 0–5%; Table 2). On the other hand, anti-Leu-3a and two other mAbs that recognize the CD4 molecule (OKT4A and anti-T4) were efficient inhibitors of the Id–anti-Id reaction. These data indicate that HF1.7 recognizes an Id determinant on anti-Leu-3a and that it may “mimic” CD4 in its binding to anti-CD4 mAbs. It is noteworthy that anti-Leu-3a, OKT4A, and anti-T4 all block *in vitro* infection by HIV (18). Thus, the ability to inhibit the Id–anti-Id reaction appears to correlate with the ability of the mAb to block HIV infection *in vitro*.

Table 2. Inhibition of binding of HF1.7 to anti-Leu-3a by various antibodies

Inhibitor	Isotype	Percent inhibition*
Anti-Leu-3a	IgG1, κ	94
OKT4A	IgG1, κ	91
Anti-T4	IgG1, κ	84
Anti-Leu-1	IgG2a, κ	0
Anti-Leu-2a	IgG1, κ	0
Anti-Leu-5b	IgG2a, κ	4
Anti-Leu-8	IgG2a, κ	5
Anti-Leu-M1	IgM, κ	3
Normal mouse IgG [†]		5

Each inhibitor was tested at a concentration of 5 μ g per well.

*Mean of triplicate determinations.

[†]Purified from pooled normal BALB/c mouse serum.




FIG. 2. Inhibition of binding of FITC-anti-Leu-3a to A3.01 cells by anti-Id mAb HF1.7. The A3.01 cells were stained with FITC-anti-Leu-3a in the presence of PBS (trace A) or PBS containing 10 μ g of HF1.7 (trace B) or 10 μ g of GB-2 (trace C).

The binding of mAb HF1.7 to anti-Leu-3a was further confirmed in another inhibition experiment using flow cytometry. Approximately 95% of cells of the human T-cell line A3.01 express surface CD4 as detected by immunofluorescence staining with anti-Leu-3a (14). Incubation of anti-Leu-3a with the HF1.7 anti-Id mAb resulted in a significant decrease in the fluorescence intensity of the anti-Leu-3a staining (Fig. 2). Anti-Leu-3a staining of the A3.01 cells was not significantly affected by prior incubation with the control anti-Id mAb. These data suggest that the anti-Id mAb can bind to anti-Leu-3a and partially inhibit anti-Leu-3a binding to surface CD4 present on human T cells. Therefore, the anti-Id mAb must recognize at least a portion of the antibody-combining site on anti-Leu-3a, based on its ability to inhibit binding to CD4 on human T cells. These characteristics further suggest that HF1.7 recognizes an Id determinant associated with the antibody-combining site on anti-Leu-3a.

To assess the expression of the antigen recognized by HF1.7 on the surface of HIV-infected cells by the anti-Id, an indirect immunofluorescence assay was performed on uninfected and continuously infected H9 cells (Fig. 3). Anti-Id staining of infected H9 cells resulted in a clear increase in fluorescence intensity, whereas uninfected H9 cells were not stained. Approximately 25% of HIV-infected




FIG. 3. Immunofluorescence profiles of uninfected (trace A) and HIV-infected (trace B) H9 cells stained with mAb HF1.7. Trace C shows GB-2 (negative control) staining of HIV-infected H9 cells.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.